- Home
- VTYX
as 04-29-2025 3:45pm EST
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 154.9M | IPO Year: | 2021 |
| Target Price: | $11.33 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.78 - $5.66 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Ventyx Biosciences Inc. (VTYX)
Latest Ventyx Biosciences Inc. News
VTYX Breaking Stock News: Dive into VTYX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists
GlobeNewswire
2 months ago
Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress
GlobeNewswire
2 months ago
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025
GlobeNewswire
3 months ago
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
TipRanks
3 months ago
Ventyx Biosciences highlights its 2025 pipeline strategy
GlobeNewswire
4 months ago
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio
Simply Wall St.
4 months ago
We're Keeping An Eye On Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate
Simply Wall St.
5 months ago
Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k
Compare VTYX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VTYX Ventyx Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.